Yervoy really needs cavatak, as it not only makes it more effective but much safer. With cavatak Yervoy had only 11% adverse effects (all related to Yervoy).
But alone:
"In the pivotal study of Yervoy in 951 patients, 52% of patients taking Yervoy had to stop treatment due to adverse events. A reason for lower adverse events with the combination treatment is that Cavatak is exposing more cancer cells to attack by Yervoy from cell lysis rather than Yervoy affecting healthy tissue in the process."
Regarding the sp, the price came down on low volumes. Perhaps this is so some transferring between funds could happen in the low 60's. There has been a lot moved around recently.
Once this is done I expect the price to rise back up, at least to the 80's and maybe to over a dollar.
The price should also rise as we get nearer to April. But of course a takeover or deal could come at any time.
cheers
VLA Price at posting:
62.0¢ Sentiment: Buy Disclosure: Held
